

FIRST REGULAR SESSION

# HOUSE BILL NO. 1154

102ND GENERAL ASSEMBLY

---

INTRODUCED BY REPRESENTATIVE HOUX.

2459H.011

DANA RADEMAN MILLER, Chief Clerk

---

## AN ACT

To amend chapter 192, RSMo, by adding thereto one new section relating to alternative therapies.

---

*Be it enacted by the General Assembly of the state of Missouri, as follows:*

Section A. Chapter 192, RSMo, is amended by adding thereto one new section, to be known as section 192.950, to read as follows:

**192.950. 1. Notwithstanding the provisions of chapter 195 or 579 to the contrary, the department of health and senior services, in collaboration with a hospital operated by an institution of higher education in this state and with a hospital or medical center operated by the United States Department of Veterans Affairs located in this state, shall conduct a study on the efficacy of using alternative medicine and therapies, including, but not limited to, the use of 3, 4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine, in the treatment of patients who suffer from posttraumatic stress disorder, treatment-resistant depression, or substance abuse disorders or who require end-of-life care.**

**2. (1) In conducting this study, the department of health and senior services, in collaboration with the hospitals or medical center described in subsection 1 of this section and subject to appropriations, shall:**

**(a) Perform a clinical trial on the therapeutic efficacy of using psilocybin in the treatment of patients who suffer from posttraumatic stress disorder, treatment-resistant depression, or substance abuse disorders or who require end-of-life care; and**

**(b) Review current literature regarding:**

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in bold-face type in the above bill is proposed language.

17           **a. The safety and efficacy of MDMA, psilocybin, and ketamine in the treatment**  
18 **of patients who suffer from posttraumatic stress disorder, treatment-resistant**  
19 **depression, or substance abuse disorders or who require end-of-life care; and**

20           **b. The access that patients have to MDMA, psilocybin, and ketamine for such**  
21 **treatment.**

22           **(2) The department of health and senior services shall prepare and submit to the**  
23 **governor, lieutenant governor, and the general assembly the following:**

24           **(a) Quarterly reports on the progress of the study; and**

25           **(b) A written report, submitted one year following the commencement of the**  
26 **study, containing the results of the study and any recommendations for legislative or**  
27 **regulatory action.**

28           **3. The department of health and senior services shall maintain the**  
29 **confidentiality of any personally identifiable protected information collected during**  
30 **the clinical trial under this section.**

31           **4. Notwithstanding any other provision of law to the contrary, the department of**  
32 **health and senior services, any health care providers, and any other person involved in**  
33 **the clinical trial under this section shall not be subject to criminal or civil liability or**  
34 **sanction under the laws of this state for participating in the trial, except in cases of gross**  
35 **negligence or willful misconduct. No health care provider shall be subject to discipline**  
36 **against his or her professional license for participation in the trial.**

✓